Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.

Literature DB >> 27331884

Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.

Chong Hyun Suh^1,2, Sree H Tirumani^3,4, Abhishek Keraliya^3,4, Kyung Won Kim¹, Nikhil H Ramaiya^3,4, Atul B Shinagare^3,4.

Abstract

The identification of characteristic genetic alteration in gynaecological malignancies has opened the door for molecular targeted therapy. The purpose of this review is to provide a primer for the radiologist on these agents with emphasis on the role of imaging in treatment response assessment and drug toxicities. The use of targeted therapy in gynaecological malignancies will likely increase in the future and make the role of the radiologist critical in response assessment and detection of toxicities.

Entities: Disease

Mesh：

Year: 2016 PMID： 27331884 PMCID： PMC5124796 DOI： 10.1259/bjr.20160086

Source DB: PubMed Journal: Br J Radiol ISSN： 0007-1285 Impact factor: 3.039

97 in total

Review 1. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544

Review 2. Tamoxifen for relapse of ovarian cancer.

Authors: C J Williams
Journal: Cochrane Database Syst Rev Date: 2001

3. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506

4. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Authors: Robert A Burger; Mark F Brady; Michael A Bookman; Bradley J Monk; Joan L Walker; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Gini F Fleming; Peter C Lim; Stephen C Rubin; Noriyuki Katsumata; Sharon X Liang
Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544

Review 5. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

Authors: L Albiges; F Chamming's; B Duclos; M Stern; R J Motzer; A Ravaud; P Camus
Journal: Ann Oncol Date: 2012-06-11 Impact factor: 32.976

6. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.

Authors: Robert L Giuntoli; Daniel S Metzinger; Connie S DiMarco; Stephen S Cha; Jeff A Sloan; Gary L Keeney; Bobbie S Gostout
Journal: Gynecol Oncol Date: 2003-06 Impact factor: 5.482

Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.

Review 1. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Review 2. Tamoxifen for relapse of ovarian cancer.

3. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

4. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Review 5. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

6. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.

Review 7. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.

Review 8. Sirolimus-associated pulmonary toxicity.

9. PML-IRIS in a patient treated with brentuximab.

10. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina.

Review 1. Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.